Relay Therapeutics announced its Q3 2026 financial results, reporting a net loss of $81.7 million and holding $849 million in cash and investments. The company is advancing its Phase 3 ReDiscover-2 trial for second-line breast cancer, expected to complete enrollment by mid-2027, and preparing for a frontline breast cancer trial. It also revealed a new mutant-selective TIE2 inhibitor program targeting vascular anomalies and will present updated data on its zovegalisib drug at the ASH Annual Meeting in December. Shannon Campbell joined as head of commercial to lead preparations for potential product launches, signaling progress toward bringing new therapies to patients.
Relay Therapeutics' stock on Pluang is priced at USD 18.07 as of Nov 05, 2026 04:11 WIB, showing a positive 3.61% change in one day. The company's market capitalization stands at $3.78 billion, reflecting significant investor interest. Trading volume reached 2,854,282 shares, indicating active market participation around the time of these corporate updates.
